Liver Cirrhosis
Conditions
Keywords
liver cirrhosis, variceal bleeding, non selective beta blockers
Brief summary
The purpose of this study is to evaluate the influence of non betablockers in gastrointestinal motility (transit time) in patients with liver cirrhosis.
Detailed description
There is some evidence that cirrhotic patients have increased gastrointestinal transit time, this issue may favor bacterial owergrowth, and consequently bacterial translocation. Translocation of bacterias and its products are linked to vascular and hemodynamics alterations that produce descompensation on the disease. There is evidence , in animal models , that the use of beta blockers favors the gastrointestinal movement; decompensated cirrhotics had significantly longer small bowel transit time as compared with compensated cirrhotics, there have described that this alteration is related to de cirrhosis severity as assessed by Child Pugh score. The purpose of this study is to evaluate the gastrointestinal transit time before and after treatment of non selective betablockers, we are going to evaluate the gastrointestinal time before and after of 4 weeks of non selectivebetablocker treatment, in decompensated cirrhotics. The gastrointestinal time is going to be evaluate by the ingestion of a device known as smart pill, that allow ambulatory monitoring of gastrointestinal transit.
Interventions
the patient is going to receive a device called smart pill before the beginning of treatment with propranolol, after the evaluation with the smart pill device, they are goning to take propranolol (dose of propranolol 80 mg per day) for 4 weeks,finally they will receive another smart pill to evaluate the second gastrointestinal transit time
Sponsors
ALDO TORRE DELGADILLO
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Cirrhosis of any ethiology * Child Pugh A, B, C without beta-blocker treatment previously (min. 1 month without treatment) * Patients with previous variceal bleeding (with liver cirrhosis) \* Patients with ascites or bacterial spontaneous peritonitis
Exclusion criteria
* Variceal disease without cirrhosis * Cirrhotics patients that use antibiotics, prebiotics and probiotics during the study period and one month previously * Patients under immunosuppressor treatment * Patients with portal thrombosis * Patients with Sd. Budd-Chiari or cava/suprahepatic thrombosis * Patients with active infection process
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Gastrointestinal transit time before and after treatment with no selective betablocker | 4 weeks of maximum non betablocker dose | gastrointestinal time evaluated by a device called Smart pill |
| Evaluatiuon of genes of tight junctions proteins before and after treatment with no selective betablocker | 4 weeks of maximum non betablocker dose | gene expression of tight junctions proteins in duodenal and gastric epithelium |
Countries
Mexico
Contacts
Primary ContactAldo Torre Delgadillo
Outcome results
None listed